{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T16:26:50Z","timestamp":1787934410255,"version":"build-2784847793"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aims to present in a large real-world cohort a diagnostic algorithm developed to facilitate the early recognition of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS), a rare disease with targeted treatment options, and to provide clinicians with a practical roadmap for navigating diagnostic challenges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study was conducted as a retroactive cross-sectional observational study. We reviewed the medical records of 6,458 pediatric and adult patients who were referred to our clinic between 2018 and 2025.\u00a0A medical algorithm was generated based on major clinical and laboratory features of APDS. Next-generation sequencing analyses were performed on patients who were appropriate for further evaluation. Variant analysis using in silico predictors and S6 phosphorylation analysis in patients carrying previously undescribed variants were conducted accordingly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this cohort of 6,458 patients, the diagnostic algorithm identified 1,138 who met at least one major clinical or laboratory criterion. After excluding 7 with a prior APDS diagnosis and 573 with other inborn errors of immunity, genetic analysis was performed in 20 consenting patients under clinical follow-up (11 [55%] female, 9 [45%] male; median age 15 years; IQR 7.5\u201324). APDS type 2 was confirmed in 1 patient; five others harbored novel variants of uncertain significance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Delayed diagnosis and treatment of APDS may result in life-threatening complications and irreversible end-organ damage. Given its heterogeneous, overlapping phenotype, timely referral for genetic testing is essential.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1735023","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:36:34Z","timestamp":1767854194000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Activated PI3K\u03b4 syndrome in inborn errors of immunity: diagnostic strategies and clinical challenges"],"prefix":"10.3389","volume":"16","author":[{"given":"Selcen","family":"Bozkurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Necmiye","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melek Yorgun","family":"Altunbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Can","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razin","family":"Amirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Mahmudov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkay Cagan","family":"Colak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Karabiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Baronio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassilios","family":"Lougaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Tessarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevgi","family":"Bilgic-Eltan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Ozen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safa","family":"Baris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Karakoc-Aydiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-019-08738-9","article-title":"Clinical, immunological, and genetic features in patients with activated PI3K\u03b4 syndrome (APDS): a systematic review","volume":"59","author":"Jamee","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1208567","article-title":"Activated PI3K\u03b4 syndrome\u2013reviewing challenges in diagnosis and treatment","volume":"14","author":"Vanselow","year":"2023","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jaci.2023.06.015","article-title":"Activated phosphoinositide 3-kinase \u03b4 syndrome: update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity","volume":"152","author":"Maccari","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2023.2210366","article-title":"Clinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan","volume":"46","author":"Moriya","year":"2023","journal-title":"Immunol Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"ltae009","DOI":"10.1093\/immadv\/ltae009","article-title":"Hyperactivation of the PI3K pathway in inborn errors of immunity: current understanding and therapeutic perspectives","volume":"4","author":"IJspeert","year":"2024","journal-title":"Immunotherapy Adv"},{"key":"B6","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/s41590-018-0182-3","article-title":"Hyperactivated PI3K\u03b4 promotes self and commensal reactivity at the expense of optimal humoral immunity","volume":"19","author":"Preite","year":"2018","journal-title":"Nat Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12706","article-title":"Activating PI3K\u03b4 mutations in a cohort of 669 patients with primary immunodeficiency","volume":"183","author":"Elgizouli","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13052-024-01662-5","article-title":"Activated phosphoinositde 3-kinase (PI3K\u03b4) syndrome: an Italian point of view on diagnosis and new advances in treatment","volume":"50","author":"Lougaris","year":"2024","journal-title":"Ital J Pediatrics"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1476218","article-title":"Technical challenges of intracellular flow cytometry-based assays as a functional complement to diagnosis of signaling defects of inborn errors of immunity: PI3K pathway as a case of study","volume":"15","author":"del Pino Molina","year":"2024","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20141759","article-title":"Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K","volume":"211","author":"Lucas","year":"2014","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.1059","article-title":"Spanish consensus on the diagnosis and management of patients with activated PI3K delta syndrome (APDS)","volume":"35","author":"Neth","year":"2025","journal-title":"J Investig Allergol Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.652405","article-title":"Activated PI3kinase delta syndrome\u2014a multifaceted disease","volume":"9","author":"Thouenon","year":"2021","journal-title":"Front pediatrics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jaci.2023.09.032","article-title":"Interim analysis: open-label extension study of leniolisib for patients with APDS","volume":"153","author":"Rao","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"110400","DOI":"10.1016\/j.clim.2024.110400","article-title":"A randomised, placebo-controlled, phase III trial of leniolisib in activated phosphoinositide 3-kinase delta (PI3K\u03b4) syndrome (APDS): Adolescent and adult subgroup analysis","volume":"270","author":"Rao","year":"2025","journal-title":"Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s13023-025-03734-z","article-title":"Overall survival among patients with activated phosphoinositide 3-kinase delta syndrome (APDS)","volume":"20","author":"Mahendran","year":"2025","journal-title":"Orphanet J Rare Diseases"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.02.004","article-title":"The european society for immunodeficiencies (ESID) registry working definitions for the clinical diagnosis of inborn errors of immunity","volume":"7","author":"Seidel","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jaip.2022.10.003","article-title":"The middle east and north africa diagnosis and management guidelines for inborn errors of immunity","volume":"11","author":"Baris","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2010-176","article-title":"Reference values for T and B lymphocyte subpopulations in Turkish children and adults","volume":"51","author":"Besci","year":"2021","journal-title":"Turkish J Med Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41597-024-03327-8","article-title":"Analysis of AlphaMissense data in different protein groups and structural context","volume":"11","author":"Tordai","year":"2024","journal-title":"Sci Data"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nprot.2015.123","article-title":"SIFT missense predictions for genomes","volume":"11","author":"Vaser","year":"2016","journal-title":"Nat Protoc"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth0810-575","article-title":"MutationTaster evaluates disease-causing potential of sequence alterations","volume":"7","author":"Schwarz","year":"2010","journal-title":"Nat Methods"},{"key":"B23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2018.12.015","article-title":"Predicting splicing from primary sequence with deep learning","volume":"176","author":"Jaganathan","year":"2019","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2892","article-title":"A general framework for estimating the relative pathogenicity of human genetic variants","volume":"46","author":"Kircher","year":"2014","journal-title":"Nat Genet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.3390\/jcm9103335","article-title":"Activated phosphoinositide 3-kinase delta syndrome 1: clinical and immunological data from an Italian cohort of patients","volume":"9","author":"Tessarin","year":"2020","journal-title":"J Clin Med"},{"key":"B26","unstructured":"The jamovi project. jamovi (Version 2.6)\n          \n          \n          2025"},{"key":"B27","unstructured":"All about APDS. What is APDS\n          \n          \n          2025"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/ACI.0000000000000947","article-title":"Monogenic forms of common variable immunodeficiency and implications on target therapeutic approaches","volume":"23","author":"Tessarin","year":"2023","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","article-title":"Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase \u03b4 syndrome 2: a cohort study","volume":"138","author":"Elkaim","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.gendis.2019.09.015","article-title":"An updated review on activated PI3 kinase delta syndrome (APDS)","volume":"7","author":"Singh","year":"2020","journal-title":"Genes Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03066-7","article-title":"Genetic etiologies and outcomes in malignancy and mortality in activated phosphoinositide 3-kinase delta syndrome: a systematic review","volume":"42","author":"B\u00fcsch","year":"2025","journal-title":"Adv Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.702872","article-title":"Disorders related to PI3K\u03b4 hyperactivation: characterizing the clinical and immunological features of activated PI3-kinase delta syndromes","volume":"9","author":"Redenbaugh","year":"2021","journal-title":"Front Pediatrics"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12790","article-title":"T and B-cell signaling in activated PI3K delta syndrome: From immunodeficiency to autoimmunity","volume":"291","author":"Preite","year":"2019","journal-title":"Immunol Rev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase \u03b4 syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2024.1279112","article-title":"Current genetic diagnostics in inborn errors of immunity","volume":"12","author":"von Hardenberg","year":"2024","journal-title":"Front Pediatrics"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1735023\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:36:35Z","timestamp":1767854195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1735023\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2025.1735023"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1735023","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"article-number":"1735023"}}